Combined – Talk Bio

ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

3 weeks ago talkbio0Tagged Bio, Combined, Frequency of Responses, IMM2510/AXN-2510, ImmuneOnco, Instill - dosing instruction imperative, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-L1xVEGF, Pharmacotherapy, safety profile

ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

1 month ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC

4 months ago talkbio0Tagged Akeso, Combined, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-1/VEGF, Pharmacotherapy, Safety, summit

Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

5 months ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso

5 months ago talkbio0Tagged Combined, Continuance of life, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso

Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

11 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses